NO20081811L - Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effekt - Google Patents
Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effektInfo
- Publication number
- NO20081811L NO20081811L NO20081811A NO20081811A NO20081811L NO 20081811 L NO20081811 L NO 20081811L NO 20081811 A NO20081811 A NO 20081811A NO 20081811 A NO20081811 A NO 20081811A NO 20081811 L NO20081811 L NO 20081811L
- Authority
- NO
- Norway
- Prior art keywords
- combination drug
- drug containing
- combination
- cerebral infarction
- probucol
- Prior art date
Links
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 title abstract 2
- 229940000425 combination drug Drugs 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003912 probucol Drugs 0.000 title abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 3
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71695405P | 2005-09-15 | 2005-09-15 | |
| US76177506P | 2006-01-25 | 2006-01-25 | |
| PCT/JP2006/318675 WO2007032557A1 (en) | 2005-09-15 | 2006-09-14 | Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20081811L true NO20081811L (no) | 2008-04-14 |
Family
ID=37420867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20081811A NO20081811L (no) | 2005-09-15 | 2008-04-14 | Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effekt |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8580818B2 (zh) |
| EP (2) | EP2275106A1 (zh) |
| JP (2) | JP5179354B2 (zh) |
| KR (1) | KR101299320B1 (zh) |
| AR (1) | AR057520A1 (zh) |
| AU (1) | AU2006289752B2 (zh) |
| BR (1) | BRPI0616223A2 (zh) |
| CA (1) | CA2620296C (zh) |
| CY (1) | CY1112716T1 (zh) |
| DK (1) | DK1942895T3 (zh) |
| ES (1) | ES2378896T3 (zh) |
| IL (1) | IL189751A0 (zh) |
| MY (1) | MY145787A (zh) |
| NO (1) | NO20081811L (zh) |
| PL (1) | PL1942895T3 (zh) |
| PT (1) | PT1942895E (zh) |
| RU (1) | RU2411945C2 (zh) |
| SG (1) | SG165379A1 (zh) |
| TW (1) | TWI372053B (zh) |
| WO (1) | WO2007032557A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR065588A1 (es) * | 2007-03-09 | 2009-06-17 | Otsuka Pharma Co Ltd | Un medicamento para tratar enfermedad pulmonar obstructiva cronica |
| AR070816A1 (es) * | 2008-03-14 | 2010-05-05 | Otsuka Pharma Co Ltd | Farmaco de combinacion para tratar trastornos vasculares |
| CN120441542B (zh) * | 2025-05-08 | 2025-09-30 | 安徽益普克医药科技发展有限公司 | 一种西洛他唑衍生物及其制备方法与用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535019A (en) | 1978-09-01 | 1980-03-11 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| JPH04193836A (ja) * | 1990-11-26 | 1992-07-13 | Banyu Pharmaceut Co Ltd | 抗高脂血症剤 |
| JPH107590A (ja) | 1996-06-24 | 1998-01-13 | Chugai Pharmaceut Co Ltd | 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤 |
| FR2751540B1 (fr) * | 1996-07-26 | 1998-10-16 | Sanofi Sa | Composition pharmaceutique antithrombotique |
| EP0946178A4 (en) | 1996-09-18 | 2003-05-07 | Merck & Co Inc | COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES |
| US6245797B1 (en) * | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| WO1999024400A1 (en) * | 1997-11-10 | 1999-05-20 | Vyrex Corporation | Probucol esters and uses thereof |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| AU5965399A (en) | 1998-10-12 | 2000-05-01 | Andreas Bockelmann | Pharmaceutically active composition |
| EP1272220B2 (en) | 2000-04-10 | 2016-07-27 | Nicholas John Wald | Formulation for the prevention of cardiovascular disease |
| US20020115728A1 (en) * | 2000-09-05 | 2002-08-22 | Roland Stocker | Compositions and methods for treating cardiovascular disorders |
| CN1582168A (zh) * | 2001-01-26 | 2005-02-16 | 先灵公司 | 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合 |
| US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| JP2003192573A (ja) | 2001-12-25 | 2003-07-09 | Otsuka Pharmaceut Factory Inc | 経口ゲル製剤 |
| TW200301135A (en) * | 2001-12-27 | 2003-07-01 | Otsuka Maryland Res Inst Inc | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
| US6743806B2 (en) * | 2002-10-23 | 2004-06-01 | Otsuka Pharmaceutical Company, Limited | Active oxygen scavenger |
| JP2005232059A (ja) * | 2004-02-18 | 2005-09-02 | Iichiro Shimomura | 低アディポネクチン血症予防・治療剤 |
| US20090227610A1 (en) | 2005-06-08 | 2009-09-10 | Kowa Company, Ltd. | Novel triglyceride reducing agent |
| JP4193836B2 (ja) | 2005-10-24 | 2008-12-10 | ブラザー工業株式会社 | インク噴射装置の製造方法 |
-
2006
- 2006-09-14 EP EP10177619A patent/EP2275106A1/en not_active Withdrawn
- 2006-09-14 BR BRPI0616223-1A patent/BRPI0616223A2/pt not_active IP Right Cessation
- 2006-09-14 PL PL06810355T patent/PL1942895T3/pl unknown
- 2006-09-14 KR KR1020087008859A patent/KR101299320B1/ko not_active Expired - Fee Related
- 2006-09-14 JP JP2008514987A patent/JP5179354B2/ja not_active Expired - Fee Related
- 2006-09-14 AU AU2006289752A patent/AU2006289752B2/en not_active Ceased
- 2006-09-14 RU RU2008114512/15A patent/RU2411945C2/ru not_active IP Right Cessation
- 2006-09-14 DK DK06810355.5T patent/DK1942895T3/da active
- 2006-09-14 SG SG201006668-6A patent/SG165379A1/en unknown
- 2006-09-14 EP EP06810355A patent/EP1942895B1/en not_active Not-in-force
- 2006-09-14 TW TW095134039A patent/TWI372053B/zh not_active IP Right Cessation
- 2006-09-14 WO PCT/JP2006/318675 patent/WO2007032557A1/en not_active Ceased
- 2006-09-14 ES ES06810355T patent/ES2378896T3/es active Active
- 2006-09-14 CA CA2620296A patent/CA2620296C/en not_active Expired - Fee Related
- 2006-09-14 US US12/065,619 patent/US8580818B2/en not_active Expired - Fee Related
- 2006-09-14 MY MYPI20080610A patent/MY145787A/en unknown
- 2006-09-14 PT PT06810355T patent/PT1942895E/pt unknown
- 2006-09-14 AR ARP060104020A patent/AR057520A1/es unknown
-
2008
- 2008-02-25 IL IL189751A patent/IL189751A0/en unknown
- 2008-04-14 NO NO20081811A patent/NO20081811L/no not_active Application Discontinuation
-
2012
- 2012-04-20 CY CY20121100376T patent/CY1112716T1/el unknown
- 2012-09-11 JP JP2012199804A patent/JP5603393B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-21 US US14/059,368 patent/US20140045889A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1942895B1 (en) | 2012-02-01 |
| CY1112716T1 (el) | 2016-02-10 |
| JP2009508804A (ja) | 2009-03-05 |
| RU2411945C2 (ru) | 2011-02-20 |
| KR101299320B1 (ko) | 2013-09-03 |
| JP5603393B2 (ja) | 2014-10-08 |
| US8580818B2 (en) | 2013-11-12 |
| MY145787A (en) | 2012-04-30 |
| PL1942895T3 (pl) | 2012-07-31 |
| US20140045889A1 (en) | 2014-02-13 |
| SG165379A1 (en) | 2010-10-28 |
| CA2620296A1 (en) | 2007-03-22 |
| KR20080049822A (ko) | 2008-06-04 |
| HK1122996A1 (zh) | 2009-06-05 |
| IL189751A0 (en) | 2008-12-29 |
| WO2007032557A1 (en) | 2007-03-22 |
| ES2378896T3 (es) | 2012-04-18 |
| JP5179354B2 (ja) | 2013-04-10 |
| RU2008114512A (ru) | 2009-10-20 |
| AU2006289752B2 (en) | 2011-06-09 |
| CA2620296C (en) | 2013-10-22 |
| DK1942895T3 (da) | 2012-03-05 |
| EP1942895A1 (en) | 2008-07-16 |
| EP2275106A1 (en) | 2011-01-19 |
| TW200744597A (en) | 2007-12-16 |
| BRPI0616223A2 (pt) | 2011-06-14 |
| JP2013014605A (ja) | 2013-01-24 |
| TWI372053B (en) | 2012-09-11 |
| AR057520A1 (es) | 2007-12-05 |
| AU2006289752A1 (en) | 2007-03-22 |
| US20090176826A1 (en) | 2009-07-09 |
| PT1942895E (pt) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008127682A3 (en) | Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor | |
| NO20083026L (no) | Terapeutisk middel for diabetes | |
| NO20092374L (no) | Forbindelser som har bade angiotensin II receptorantagonisme og PPARy aktiverende aktiviteter | |
| HRP20141248T1 (en) | 4-(indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as ep4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | |
| WO2008097428A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2010004965A (es) | Derivados de amida como moduladores de la sirtuina. | |
| IL194831A0 (en) | Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions | |
| NO20070247L (no) | Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase | |
| BR122021002201A8 (pt) | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença | |
| TW200736247A (en) | Compounds for the treatment of inflammatory disorders | |
| EP2190428A4 (en) | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES | |
| MX2009013976A (es) | Compuestos imidazotiazol moduladores de sirtuina. | |
| ATE524450T1 (de) | 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren | |
| WO2008007211A8 (en) | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds | |
| WO2006094209A3 (en) | N-benzimidazolylalkyl-substituted amide sirtuin modulators | |
| NO20082497L (no) | Diarylureaer for behandling av pulmonal hypertensjon | |
| MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
| WO2009121939A3 (en) | C-aryl glycoside compounds for the treatment of diabetes and obesity | |
| NO20081811L (no) | Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effekt | |
| DK2336120T3 (da) | Kombinationer, der indeholder amid-substituerede indazoler som poly(adp-ribose)polymerase (parp)-hæmmere | |
| MY181731A (en) | Azole benzene derivative | |
| EP2086568A4 (en) | ACTIVATED PROTEIN C-VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY, BUT REDUCED PROTECTION-LIMITING ACTIVITY | |
| ATE476422T1 (de) | Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung | |
| NO20090646L (no) | Xinafoatsalt av en substituert 5-oksazol-2-yl-kinolinforbindelse | |
| UA107561C2 (xx) | Поліморфні форми ацилсульфонамідів |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |